Pacific Channel has provided business planning and product development support to a British company, Indigix, which raised seed capital of £930,000 (NZ$1.926 million).
The seed investment was led by London-based Imperial Innovations Group plc (AIM: IVO), a leading technology commercialisation and investment company, alongside Kurma BioFund, a Paris-based life sciences fund.
Pacific Channel has provided general management, project planning, budgeting and investment statement preparation services to Indigix and continues to advise the company following the seed funding round.
Indigix is developing a novel platform technology that enables it to engineer synthetic molecules for modifying defined immunological responses in a variety of major medical diseases. Potential applications for Indigix’s technology include the treatment of diarrhoeal diseases, inflammatory bowel disease and improved wound healing.
Dr Robert Feldman, Executive Director of Pacific Channel Ltd. said, “It has been a real pleasure to have been involved with the founding and development of Indigix and it is most gratifying to see the successful seed investment and to have been part of the team that has generated the success.”
Click here to view Indigix’s press release.
For further information, please contact:
Dr Robert Feldman
Executive Director
